Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-001 prime-boost with H5N1 vaccine in healthy adults
2015-001979-46Phase 2Completed
- Sponsor
- Scinai Immunotherapeutics Ltd.
- Start
- Jun 2015
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of multimeric-001 and h5n1 monovalent influenza vaccine in influenza (3 arms), sponsored by Scinai Immunotherapeutics Ltd. Primary endpoints: Cellular immune response, Solicited adverse events and 1 more. Started Jun 2015; status: completed.
02
Drugs
multimeric-001h5n1 monovalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2015-001979-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001979-46.